Skip to main content

Table 1 Patient characteristics (N=38)

From: French “real life” experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia

Patient characteristics Number (%)
Gender: male/female 22/16 (58%/42%)
Median age at diagnosis, years (range) 4 (0-16)
Median age at clofarabine treatment onset, years (range) 7 (0-18)
WBC count at diagnosis x109/l (range) 7.45 (0.9-675)
Immunophenotype  
 B lineage 33 (87%)
 T lineage 2 (5%)
 Biphenotypic 3 (8%)
CNS involvement at diagnosis 2
Adverse cytogenetics  
 t(4;11) 1
 Hypodiploid karyotype 2
First line protocol  
 FRALLE 2000 17
 EORTC 58951 17
 ELAM 02 1
 Interfant 2006 3
Refractory to initial treatment 0
Number of earlier therapies, mean (range) 2.5 (1-4)
Previous hematopoietic stem-cell transplantation 10